Gilead­'s HIV drug De­scovy wins Chi­na's en­dorse­ment; Re­vance in­vestors smile as frown lines drug suc­ceeds piv­otal ...

7 years ago
News Briefing

Bis­pecifics vs CAR-T: An­a­lysts se­lect the big win­ners — and losers — at #ASH18's biggest ever dat­a­palooza

7 years ago
R&D

The Great Phar­ma Brex­it? An End­points News snap poll finds most life sci­ences in­sid­ers pre­dict­ing a de­ba­cle for the ...

7 years ago

Van­da's PhII da­ta of­fer hope for gas­tro­pare­sis pa­tients who have seen no new treat­ments in decades

7 years ago
R&D

No­var­tis plots to re­tain hives pa­tients with mon­o­clon­al an­ti­body that out­shines Xo­lair

7 years ago
R&D

#ASH18: Can Am­gen break through the BC­MA CAR-T line and take a BiTE of the mul­ti­ple myelo­ma mar­ket? It won't be quick ...

7 years ago
R&D

#ASH18: Al­lo­gene ticks off a high CR rate for up­dat­ed off-the-shelf CAR-T pi­o­neer. But get­ting just the right kind of ...

7 years ago
R&D

#ASH18: Leg­end Biotech — al­lied with J&J now — con­tin­ues to wow the crowd with their BC­MA CAR-T up­date. What will ...

7 years ago
R&D

#ASH18: BeiGene works to bust through the check­point crowd with a piv­otal read­out that proves its PD-1 is bet­ter than ...

7 years ago
R&D

GAO pokes holes in FDA's or­phan des­ig­na­tion process; Take­da Tra­di­tion­al­ists make one more ap­peal against Shire buy­out ...

7 years ago
News Briefing

No­var­tis gains pri­or­i­ty re­view for SMA gene ther­a­py as in­vestors grap­ple with stick­er shock

7 years ago
Pharma
Cell/Gene Tx

Armed with up­dat­ed 24-week PhI­II da­ta, GBT con­vinces FDA to re­view sick­le cell drug un­der ac­cel­er­at­ed path­way

7 years ago
R&D

Red­Hill's an­tibi­ot­ic Tal­i­cia edges clos­er to ap­proval, af­ter sec­ond suc­cess­ful Phase III study

7 years ago
R&D

All in: No­var­tis adds an­oth­er drug to its fast-grow­ing ra­dio­phar­ma­ceu­ti­cals di­vi­sion

7 years ago
R&D
Pharma

Fi­nal­ly sat­is­fied with Oc­u­lar's man­u­fac­tur­ing set­up, FDA ap­proves eye drug/de­vice Dex­ten­za

7 years ago
Pharma

GSK bags Tesaro for $5B as it leaps back in­to com­mer­cial on­col­o­gy and beefs up can­cer drug pipeline

7 years ago
Deals

J&J pays $500M in cash to grab rights to a new star can­cer drug at ar­genx

7 years ago
R&D
Pharma

#ASH18: Blue­bird and Cel­gene didn’t 'break' their next-gen BC­MA CAR-T, so now they’ll dou­ble down on the dose and ...

7 years ago
R&D

#ASH18: Gilead posts im­pres­sive sur­vival rates for Yescar­ta — but sales re­main lean

7 years ago
R&D

#ASH18: Cel­gene of­fers up a stel­lar com­plete re­sponse rate for JCAR017. Will any­one no­tice?

7 years ago
R&D

#ASH18: Re­gen­eron's bis­pe­cif­ic REGN1979 of­fers eye-catch­ing 80% CR rate in fol­lic­u­lar lym­phoma, spurring swift shift ...

7 years ago
R&D

#ASH18: Ac­celeron and Cel­gene take cen­ter stage with a pair of PhI­I­Is for lus­pa­ter­cept they be­lieve will back up ...

7 years ago
R&D

As­traZeneca's res­pi­ra­to­ry team ac­knowl­edges its lat­est set­back, tri­al flops

7 years ago
R&D

FSD Phar­ma scoops GW Phar­ma ex­ec to guide cannabi­noid de­vel­op­ment; Zealand Phar­ma is look­ing for a new CEO

7 years ago
Peer Review
First page Previous page 991992993994995996997 Next page Last page
A service from the Financial Times